English | Español
Patient Daily | Mar 4, 2026

FDA proposes regulatory path for individualized gene editing therapies targeting rare diseases
Patient Daily | Mar 4, 2026

Congress approves record $315 million for ALS research amid new treatment efforts
Patient Daily | Mar 4, 2026

Appellate court rules for REGENXBIO over Sarepta in gene therapy patent case
Patient Daily | Mar 4, 2026

Novo Nordisk’s obesity drug fails key test against Eli Lilly rival
Patient Daily | Mar 4, 2026

Gilead announces plan to acquire Arcellx for $7.8 billion ahead of FDA decision
Patient Daily | Mar 4, 2026

Gene therapies for sickle cell disease face slow uptake despite early promise
Patient Daily | Mar 4, 2026

Study finds bilingualism does not disrupt parent-child brain synchrony during play
Patient Daily | Mar 4, 2026

Study shows high rate of off-label antipsychotic use among Finnish seniors

Trending
+ Pharmaceuticals
Patient Daily | Mar 22, 2026

BioMarin pauses dosing and enrollment in two Voxzogo studies after safety signal
+ Regulatory
Patient Daily | Mar 20, 2026

Neurosurgeon DiGiorgio on 340B: '340B also takes money from taxpayers and makes everyone’s health insurance more expensive'
+ Pharmaceuticals
Patient Daily | Mar 22, 2026

FDA rejects REGENXBIO’s Hunter syndrome therapy as Denali awaits decision on rival drug
+ Pharmaceuticals
Patient Daily | Mar 25, 2026

Revolution and Ascendis identified as top buyout targets amid speculation of industry mega-merger